GYRE (Gyre Therapeutics) FCF Margin % : -12.57% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gyre Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-3.5 Mil. Gyre Therapeutics's Revenue for the three months ended in Dec. 2024 was $27.9 Mil. Therefore, Gyre Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -12.57%.

As of today, Gyre Therapeutics's current FCF Yield % is -0.82%.

The historical rank and industry rank for Gyre Therapeutics's FCF Margin % or its related term are showing as below:

GYRE' s FCF Margin % Range Over the Past 10 Years
Min: -6.4 Med: 9.64 Max: 15.25
Current: -6.4

During the past 4 years, the highest FCF Margin % of Gyre Therapeutics was 15.25%. The lowest was -6.40%. And the median was 9.64%.

GYRE's FCF Margin % is ranked better than
73.06% of 1017 companies
in the Biotechnology industry
Industry Median: -142.95 vs GYRE: -6.40

Gyre Therapeutics FCF Margin % Historical Data

The historical data trend for Gyre Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics FCF Margin % Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

FCF Margin %

13.73

5.55

15.25

-6.40

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial						3.81	9.76	-27.55	4.04	-12.57

Competitive Comparison of Gyre Therapeutics's FCF Margin %

For the Biotechnology subindustry, Gyre Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's FCF Margin % falls into.

Save

Gyre Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gyre Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-6.769	/	105.757
	=	-6.40 %

Gyre Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-3.503	/	27.872
	=	-12.57 %

Gyre Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.